Cleveland BioLabs and Cleveland Clinic Demonstrate Accelerated Recovery of Limb Function With Protectan CBLB502 in

Wed Aug 13, 2008 8:30am EDT

* Reuters is not responsible for the content in this press release.

  BUFFALO, NY, Aug 13 (MARKET WIRE) -- 
Cleveland BioLabs, Inc. (NASDAQ: CBLI) and founding partner Cleveland
Clinic reported today that CBLI's lead product, Protectan CBLB502,
currently being developed as a radioprotectant and radiomitigator,
demonstrated efficacy in animal models of tourniquet injury. This finding
is the result of pre-clinical studies funded by a grant from the
Department of Defense to research the use of Protectans in tourniquet and
other ligation-reperfusion battlefield injuries, where blood flow is
stopped and then restored after a prolonged period of time.

    Tourniquet injury is also frequently associated with natural disaster
conditions, as well as during other situations involving limb wounds or
trauma. This injury is caused by prolonged deficit of oxygen supply, or
ischemia, followed by rapid onset of oxidative stress at the time of
tourniquet removal and results in irreversible tissue damage. Such damage
often necessitates amputation of the limbs, which has restricted the use
of this otherwise life saving device.

    "The effect of CBLI's compound on limb recovery in our animal model of
tourniquet-induced injury is encouraging and the efficacy with which it
protects warrants continued investigation," said Robert Fairchild, Ph.D.,
of Cleveland Clinic's Lerner Research Institute. "These results will allow
us to project the potential use of this compound for multiple applications
beyond tourniquet injury -- from kidney and heart ischemia to reducing the
rapid inflammation normally observed in transplanted organs, exploring all
situations with similar mechanisms of tissue injury."

    In an animal model of tourniquet-mediated limb injury simulating the
situation occurring in humans, it has been demonstrated that injection of
Protectan CBLB502 within 30 minutes of tourniquet removal leads to a
marked reduction in the severity of injury, including reductions in
tissue edema, pro-inflammatory cytokine production and leukocyte
infiltration leading to accelerated recovery of limb function.

    "The fact that Protectan CBLB502 demonstrated results even after the
removal of a tourniquet, could make it particularly practical for
battlefield conditions or other types of civilian emergency use, since it
can be applied after an injured subject is delivered to the site of
treatment," said Andrei Gudkov, Ph.D, D. Sci., Chief Scientific Officer of
Cleveland BioLabs and inventor of the technology.

    About Cleveland BioLabs, Inc.

    Cleveland BioLabs, Inc. is a drug discovery and development company
leveraging its proprietary discoveries around programmed cell death to
develop treatments for cancer and protection of normal tissues from
exposure to radiation and other stresses. The Company has strategic
partnerships with the Cleveland Clinic, Roswell Park Cancer Institute,
ChemBridge Corporation and the Armed Forces Radiobiology Research
Institute. To learn more about Cleveland BioLabs, Inc., please visit the
company's website at http://www.cbiolabs.com.

    The Cleveland Clinic ("CC") holds a minority equity ownership interest in
Cleveland BioLabs Medical, Inc. ("Cleveland BioLabs"), and has the right
to receive royalties from Cleveland BioLabs. Certain CC officials serve on
the Cleveland BioLabs Board of Directors. Institutional and individual
conflicts of interest in research are disclosed to, and reviewed and
managed by, CC's Conflicts of Interest Committee and are subject to
approval by CC's Institutional Review Board and/or Institutional Animal
Care and Use Committee.

    This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of
this press release, and involve certain risks and uncertainties. The
Company's actual results could differ materially from those anticipated in
these forward-looking statements as a result of various factors. Some of
the factors that could cause future results to materially differ from the
recent results or those projected in forward-looking statements include
the "Risk Factors" described in the Company's periodic filings with the
Securities and Exchange Commission.

    

Contact:
Rachel Levine
Director Corporate Development & Communications
Cleveland BioLabs, Inc.
T: (646) 284-9439
E: rlevine@cbiolabs.com

Copyright 2008, Market Wire, All rights reserved.

-0-